Emerging vaccines for influenza

被引:19
作者
Tosh, Pritish K. [1 ,2 ]
Man, Gregory A. [1 ,3 ]
机构
[1] Mayo Clin, Coll Med, Mayo Clin Vaccine Res Grp, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, Div Infect Dis, Rochester, MN 55905 USA
[3] Mayo Clin, Coll Med, Mayo Vaccine Res Grp, Rochester, MN 55905 USA
关键词
influenza; influenza vaccine;
D O I
10.1517/14728214.13.1.21
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Influenza remains one of the leading causes of morbidity and mortality worldwide. The available vaccines are least effective in the populations at greatest risk - children, the elderly, and the immuno-compromised. Furthermore, avian influenza and other novel strains have the potential to cause the next influenza pandemic. Research efforts have accelerated worldwide to develop new vaccines to provide better immunity against annual epidemics and a potential pandemic. Objective: To summarize the global research efforts at developing new influenza vaccines, adjuvants, and delivery devices. Method: MEDLINE and Pharmaprojects databases were searched for publications and continuing research on new influenza vaccine technologies. Results/conclusions: Technologies such as DNA vaccines, live recombinant viral vector vaccines, and virus-like particles have shown significant promise for immunogenicity and protection from experimental challenge to influenza. New modalities for vaccine delivery and methods for rapid vaccine production are also being investigated. With the possibility of an influenza pandemic increasing the need to develop new vaccines, the global research community has made large strides to meet this challenge.
引用
收藏
页码:21 / 40
页数:20
相关论文
共 91 条
[11]   The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children [J].
Belshe, RB ;
Mendelman, PM ;
Treanor, J ;
King, J ;
Gruber, WC ;
Piedra, P ;
Bernstein, DI ;
Hayden, FG ;
Kotloff, K ;
Zangwill, K ;
Iacuzio, D ;
Wolff, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (20) :1405-1412
[12]   ANTIBODY-RESPONSE TO THE M2-PROTEIN OF INFLUENZA A-VIRUS EXPRESSED IN INSECT CELLS [J].
BLACK, RA ;
ROTA, PA ;
GORODKOVA, N ;
KLENK, HD ;
KENDAL, AP .
JOURNAL OF GENERAL VIROLOGY, 1993, 74 :143-146
[13]   Vaccine delivery methods using viral vectors [J].
Brave, Andreas ;
Ljungberg, Karl ;
Wahren, Britta ;
Liu, Margaret A. .
MOLECULAR PHARMACEUTICS, 2007, 4 (01) :18-32
[14]   Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:: phase I randomised trial [J].
Bresson, Jean-Louis ;
Perronne, Christian ;
Launay, Odile ;
Gerdil, Catherine ;
Saville, Melanie ;
Wood, John ;
Hoeschler, Katja ;
Zambon, Maria C. .
LANCET, 2006, 367 (9523) :1657-1664
[15]   Effectiveness and cost-benefit of influenza vaccination of healthy working adults - A randomized controlled trial [J].
Bridges, CB ;
Thompson, WW ;
Meltzer, MI ;
Reeve, GR ;
Talamonti, WJ ;
Cox, NJ ;
Lilac, HA ;
Hall, H ;
Klimov, A ;
Fukuda, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (13) :1655-1663
[16]   Genetic and phenotypic stability of cold-adapted influenza viruses in a trivalent vaccine administered to children in a day care setting [J].
Buonagurio, DA ;
O'Neill, RE ;
Shutyak, L ;
D'Arco, GA ;
Bechert, TM ;
Kazachkov, Y ;
Wang, HP ;
DeStefano, J ;
Coelingh, KL ;
August, M ;
Parks, CL ;
Zamb, TJ ;
Sidhu, MS ;
Udem, SA .
VIROLOGY, 2006, 347 (02) :296-306
[17]  
BURT D, 2002, NASAL PROTEOSOME FLU
[18]  
*CDC, KEY FACTS AV INFL BI
[19]   Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial [J].
Cha, TA ;
Kao, K ;
Zhao, J ;
Fast, PE ;
Mendelman, PM ;
Arvin, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (02) :839-845
[20]   COMPARISON OF HETEROTYPIC PROTECTION AGAINST INFLUENZA A/TAIWAN/86 (H1N1) BY ATTENUATED AND INACTIVATED VACCINES TO A/CHILE/83-LIKE VIRUSES [J].
CLOVER, RD ;
CRAWFORD, S ;
GLEZEN, WP ;
TABER, LH ;
MATSON, CC ;
COUCH, RB .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (02) :300-304